<DOC>
	<DOC>NCT00257660</DOC>
	<brief_summary>The aim of this study is to demonstrate the effectiveness and safety of 500 units of Dysport manufactured at a new manufacturing facility in Europe.</brief_summary>
	<brief_title>Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (DysportÂ®) for the Treatment of Cervical Dystonia</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Cervical dystonia with at least 18 months since onset, and previously untreated with botulinum toxin or previously treated with botulinum toxin type A or B with a minimum interval of 16 weeks since the last injection and having returned at least to their usual pretreatment status TWSTRS severity, disability and total scores meeting the defined criteria at baseline Pure anterocollis or pure retrocollis In apparent remission from cervical dystonia Previous poor response to the last two botulinum toxin type A or type B treatments Being treated with type B toxin due to lack of efficacy to type A toxin or have known neutralizing antibodies to type A toxin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>